Diversifying your telehealth services? Patient outcomes should drive your GTM.

---

Every few weeks I sit with a founder who has already decided what they’re building next. A second service line. A third. The logic is almost always the same: demand is up, a competitor just launched it, and adding it should add growth.

I understand the instinct. But it’s wrong.

Diversifying your telehealth services is not the same as growing. A new offering only grows you if it proves useful to the patients you already serve. If it doesn’t improve someone’s health, it isn’t a growth lever. It’s a line item you now have to staff, support, and defend.

I’ve sat on both sides of this. I’ve watched teams bolt on a service that looked like growth for a quarter and quietly became a tax on everything that was working. So here’s the test I’d apply before you build anything new this year.

The one-stop shop trap

“Become a one-stop shop for patient health” is the most repeated growth strategy in telehealth this year. It can work, but only when done right. Breadth is only an asset when every service under your brand produces meaningful outcomes.

Demand for proactive health has moved mainstream. McKinsey puts the U.S. wellness market north of $500 billion, with most consumers now calling wellness a top priority. That pull is strong, and it tempts operators to widen the menu fast.

But a wide menu of mediocre offerings doesn’t read as convenience to a patient. It reads as a brand that stopped being careful. In healthcare, the moment a patient questions whether you’re careful, you’ve lost the thing that made them stay.

Before you widen the menu, pressure-test the instinct:

• Are you adding this to deepen care for the patients you already have, or just to widen what you sell?
• Can you actually deliver it well, with protocols, trained clinicians, and follow-up?
• Would your clinicians recommend it to a patient they care about?

If the honest answer to any of those is shaky, you’re not building an integrated care experience. You’re attaching a service and calling it growth.

The only test a new offering has to pass

Here’s the filter I’d run every offering through before it gets a dollar or a headcount: does it measurably improve the patient’s health?

Not “will patients buy it.” Plenty of things sell. Novelty sells, convenience sells, a slick funnel sells. None of that tells you the patient ended up better off, and that’s the only thing I actually care about here. When patients get results, they stay—and a care model built on giving great care is the foundation of a business built to last.

That distinction sounds obvious. In practice, most “what should we add next” conversations skip right past it and jump straight to market size.

You can test for patient value before you commit to building:

• Talk to your clinicians. If the people who would deliver it are hesitant, listen to why.
• Talk to your existing patients. Is there an unmet need here, or are you reacting to a headline?
• Check the clinical evidence. Who benefits from this, and who doesn’t?
• Ask whether it fits the population you already serve.

“Patients will buy it” and “patients will be better off” are two different claims. Only the second one compounds into lasting growth.

What “growth for growth’s sake” actually costs you

A poorly planned offering becomes a silent growth killer. It underperforms bit by bit, month by month, while it eats away at your time and headcount.

I’ve seen this play out enough times to know the pattern. A competitor ships something, a board member asks why we don’t have it, and a new line lands on the roadmap. Speed wins over readiness. By the time the first patients come through, the cracks show up exactly where you’d expect, and the results are forgettable because no one built for anything better.

Then the drag starts:

• Support load climbs as confused patients ask questions no one scripted for.
• Clinician time gets pulled toward a line that isn’t working.
• Refunds and drop-off eat the early revenue.
• Focus drifts from the part of the business that was healthy.

The cost I worry about most never shows up on a dashboard. Revenue you can usually win back, but a weak offering erodes the trust with patients and clinicians that makes your good ones work, and that’s slow to return. It can look like growth for a quarter, then quietly stall.

Make patient outcomes the center of your go-to-market strategy

Patient outcomes should inform decisions throughout the go-to-market process, from initial product development through launch and ongoing optimization.

When outcomes are the filter, a few things change:

• Every “should we add this” decision runs through one question first: will it improve outcomes?
• Clinicians help design the offering, not just deliver it.
• The care model is built around follow-up and adherence, not a one-time transaction.
• Success metrics grow past acquisition to include outcomes, adherence, and patient-reported results.

This is also the version of growth that lasts. When patients get measurably better, they stay, and patient retention stops being a tactic you chase. It becomes a byproduct of care that works. We’ve written before about why whole-health support changes the math on a single-condition program, and the same logic carries over here. Better outcomes and more convenient care keep patients around.

Patient experience shapes clinical outcomes

Here’s the piece most teams underbuild. The experience after the sale produces the outcome. Communication, access to a clinician, and support between visits are what lead to better adherence. Get it wrong and the best protocol on paper still fails.

A strong patient experience includes:

• Clear communication. They know what’s happening, what’s next, and who to reach.
• A clinician who’s present. Patients can ask questions and receive appropriate guidance when their needs change.
• Support between visits. Patients have help when concerns arise, not only at checkout.
• Continuity of care. The plan evolves with them instead of ending after the first prescription.

A patient who gets this experience sticks with the plan, and adherence is where results come from. One who feels dropped after checkout won’t finish and won’t come back. It’s also where trust is won or lost, and trust is what keeps a patient.

So don’t just ask whether the clinical model works. Ask whether you can deliver this experience from day one. If you can’t, don’t launch it.

Peptides are the use case right now

Peptides are the clearest live example of this whole argument. Awareness is climbing fast, patients are asking, and the temptation to attach a peptide line before you’ve thought it through is strong.

Peptides have meaningful clinical potential for specific, targeted purposes. They are not the miracle category some of the consumer marketing suggests, and the broad human research isn’t there yet to support the bigger claims being made about them. Lastly, the line between what’s eligible for patient-specific compounding and what isn’t can move with little warning.

Here’s how I’d consider whether peptides serve your patients, versus adding them because the market is loud:

• Look at the clinical evidence and the appropriate use cases. Who benefits, and who doesn’t?
• Check for a true unmet need in your patient population, not demand manufactured by the trend.
• Be honest about clinician readiness. Can you deliver it safely, with proper screening, labs, and monitoring?
• Build to the regulations from the start. Peptides are not FDA-approved, and patient-specific (503A) compounding carries guardrails you have to meet to keep patients safe.
• Scrutinize sourcing and quality, and track how the rules around specific peptides are evolving, which can shift quickly.
• Have clear clinical protocols and escalation pathways in place. Not every patient is a fit, and you have a responsibility to keep them safe.

How to know it’s working, and when to cut it

An offering earns its place on evidence. Pick your outcome metrics before you launch, and the numbers will tell you whether it’s working.

Track four things:

• Clinical outcomes. Biomarkers, symptom scores, whatever result the offering was supposed to deliver.
• Patient-reported results. Understand whether patients experience meaningful improvements in their health.
• Adherence and completion. Monitor whether patients follow the care plan and complete the program.
• Clinical confidence. Collect feedback from clinicians on the service’s effectiveness, safety, and suitability for patients.

Give it a fair window, then make the call. Some signals land in weeks, others take quarters.

It comes down to simple business economics. If it doesn’t do what it promised, people won’t want it. If you didn’t build the offering around patient outcomes, you’re not likely to see the growth you’re chasing. 

So, if the demand isn’t there, or you don’t have the resources to build it right, cut it. Protecting the patient protects the brand. Every time.

One thing I’d tell a founder before they diversify this year

Anchor every new offering to a patient outcome before you build it. 

Go deep before you go wide. And get comfortable saying no, because the discipline to pass on something is most of the job.

Make sure you can deliver quality and follow-up at the scale you’re planning for before you launch. Build clinical governance and the rules into the plan early. And diversify to serve the patients you already have better. 

Do that, and growth tends to take care of itself, because patients who get better are patients who stay.

If you’re ready, OpenLoop can help you build it faster.

Everything above comes down to one idea: an offering only grows you if patients end up better off. The hard part is standing up the clinician network, the protocols, the lab and pharmacy relationships, and the clinical governance to deliver on it, then keeping all of it current as the rules change. That’s exactly what we’re doing here at OpenLoop®. 

We power the clinical infrastructure behind 400+ virtual care brands serving over one million patients a month, so you can build offerings around patient outcomes from day one, under your own brand. Talk to our team about what that could look like for your organization.

---

Compounded medications are not FDA-approved. FDA does not review compounded drugs for safety, efficacy, or quality. Compounded medications require a prescription following an appropriate clinical evaluation. No prescription is guaranteed. Peptide availability varies based on clinical appropriateness, applicable federal and state laws, pharmacy availability, and other regulatory requirements. Not all peptide therapies are available in all states or through all pharmacies. See our website for full details, important patient information, and applicable restrictions.

This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.